Tebanicline, also known as ABT-594, is primarily researched for its potential in pain management, particularly in treating chronic pain conditions. It acts as a selective agonist for nicotinic acetylcholine receptors, which are involved in modulating pain signals in the nervous system. This mechanism makes it a candidate for addressing neuropathic pain, where traditional painkillers like opioids may be less effective or carry higher risks of addiction and side effects. Its application is being explored in clinical settings to provide a non-opioid alternative for patients suffering from severe, long-term pain. Additionally, its potential to reduce inflammation and improve pain thresholds has garnered interest in further therapeutic studies.